Acadia Healthcare Company Inc vs Kinross Gold Corporation — how do they compare? Acadia Healthcare Company Inc trades at $31.76 (market cap $2.90B), while Kinross Gold Corporation trades at $27.68 (market cap $32.29B). The key difference: Kinross Gold Corporation is far larger — about 11.1× Acadia Healthcare Company Inc's market cap, and Kinross Gold Corporation pays a 0.59% dividend while Acadia Healthcare Company Inc pays none. Which is the better fit depends on your goals.
| ACHC | KGC | |
|---|---|---|
Market Cap | $2.90B | $32.29B |
Sector | Health | Basic Materials |
52-Week High | $35.61 | $38.06 |
52-Week Low | $11.68 | $18.70 |
Enterprise Value | $5.29B | $30.37B |
Dividend Yield | — | 0.59% |
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.14, down 2.01% today, with a neutral technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $0.38, beating estimates, but maintains a net loss of -$1.10B for 2025. Analyst consensus is bullish with a $36.00 price target, though ongoing legal investigations and negative profit margins present headwinds. Cash flow from operations improved to $211M in 2026, supporting operational stability amid challenges.
The outlook for ACHC hinges on execution of its turnaround strategy and resolution of legal issues. Upside potential exists if EBITDA guidance improvements and admissions growth persist, but risks from litigation and sustained losses warrant caution. The stock's current valuation at a P/E of 19.82 and P/S of 0.84 may attract value investors if profitability recovers.
KGC trades at $27.40, down 0.87% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings of $0.71 per share, beating estimates, and maintains robust fundamentals with a P/E of 10.36 and net income margin of 37.52%. Recent news includes an S&P credit upgrade to 'BBB' and progress on the Lobo-Marte project, signaling operational strength.
The outlook is positive, driven by earnings beats, rising free cash flow, and a consensus price target of $37.20 offering ~36% upside. Risks include cost pressures, gold price volatility, and execution of growth projects. Analyst sentiment is bullish with 59% buy ratings, but investors should monitor Q3 2026 results for sustained momentum.
Trailing returns across standard periods
Latest headlines on both assets
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →